---

UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549

FORM 10-QSB

(Mark One)

|[X]   | Quarterly Report Under Section 13 Or 15(d) Of
      The Securities Exchange Act Of 1934
|----- | ---------------------------------------------------------------------------------------
|      |                                                                                        
|      | For the quarterly period ended January
      31, 2007                                  
|      |                                                                                        
|[   ] | Transition Report Under Section 13 Or 15(d) Of
      The Exchange Act                  
|      |                                                                                        
|      | For the transition period from _________ to
      _________                            

COMMISSION FILE NUMBER000-51573

VITAVEA INC.(Exact name of
small business issuer as specified in its charter)

|NEVADA                                           | 20-0848675                       
|------------------------------------------------ | ---------------------------------
|(State or other jurisdiction of incorporation or | (IRS Employer Identification No.)
|organization)                                    |                                  

1323 Lincoln Street, #204Bellingham, WA
98229(Address of principal executive offices)

(360) 483-8248(Issuer's telephone
number)

Not Applicable(Former name, former address and
former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days.    Yes [ X ]No [    ]

Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes [   
] No [ X ]

State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date: As of March 22,
2007, the Issuer had 110,973,358 Shares of Common Stock outstanding.

Transitional Small Business Disclosure Format (check one): Yes
[    ] No [X]

---

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

2

---

VITAVEA INC.

(formerly GA Computer Sciences Inc.)

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in U.S. Dollars)

January 31, 2007(Unaudited)

---

VITAVEA INC.
  (formerly GA Computer Sciences Inc.)
  (A Development Stage Company) CONSOLIDATED BALANCE SHEET
  (Expressed in U.S. Dollars)
  (Unaudited)

|                                                                 |   | January 31, |  
|---------------------------------------------------------------- | - | ----------- | -
|                                                                 |   | 2007        |  
|                                                                 |   |             |  
|ASSETS                                                           |   |             |  
|                                                                 |   |             |  
|Current Assets                                                   |   |             |  
|Cash and cash equivalents                                        | $ | 51,868      |  
|Other receivables                                                |   | 344,915     |  
|Inventory                                                        |   | 488,086     |  
|Prepaid expenses                                                 |   | 6,452       |  
|Deferred acquisition costs
      (Note 3)                        |   | 1,216,116   |  
|Deferred
      tax asset, less valuation allowance of $1,064,548 |   | -           |  
|Total Current Assets                                             |   | 2,107,437   |  
|                                                                 |   |             |  
|Equipment (Note 4)                                               |   | 1,923       |  
|Patent
      (Note 4)                                            |   | 24,834      |  
|                                                                 |   |             |  
|Total Assets                                                     | $ | 2,134,194   |  
|                                                                 |   |             |  
|LIABILITIES AND STOCKHOLDERS EQUITY                             |   |             |  
|                                                                 |   |             |  
|Current Liabilities                                              |   |             |  
|Accounts payable and accrued
      liabilities                   | $ | 1,291,603   |  
|Loans
      payable current (Note 5, 6)                         |   | 216,651     |  
|Total Current Liabilities                                        |   | 1,508,254   |  
|                                                                 |   |             |  
|                                                                 |   |             |  
|Commitments (Note 3, 9)                                          |   |             |  
|                                                                 |   |             |  
|Stockholders Equity                                             |   |             |  
|Common stock (Note 7)                                            |   |             |  
|Authorized                                                       |   |             |  
|750,000,000
      common shares, par value $0.001                |   |             |  
|Issued
      and outstanding                                     |   |             |  
|110,025,308                                                      |   | 110,025     |  
|Additional paid-in capital                                       |   | 3,878,945   |  
|Accumulated other comprehensive
      loss:                      |   |             |  
|Foreign currency cumulative
      translation adjustment         |   | (232,005    | )
|Deficit accumulated during the development
      stage           |   | (3,131,025  | )
|Total Stockholders
      Equity                                 |   | 625,940     |  
|                                                                 |   |             |  
|Total Liabilities
      and Stockholders Equity                 | $ | 2,134,194   |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-2

---

VITAVEA INC.
  (formerly GA Computer Sciences Inc.)
  (A Development Stage Company) CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
  (Expressed in U.S. Dollars)
  (Unaudited)

|                                            |   | Cumulative       |   |   |             |   |   |              |  
|------------------------------------------- | - | ---------------- | - | - | ----------- | - | - | ------------ | -
|                                            |   | Amounts          |   |   | Three       |   |   | Three        |  
|                                            |   | From Inception   |   |   | Months      |   |   | Months       |  
|                                            |   | (March 31, 2004) |   |   | Ended       |   |   | Ended        |  
|                                            |   | to January 31,   |   |   | January 31, |   |   | December 31, |  
|                                            |   | 2007             |   |   | 2007        |   |   | 2005         |  
|                                            |   |                  |   |   |             |   |   |              |  
|REVENUE                                     |   |                  |   |   |             |   |   |              |  
|Sales                                       | $ | 27,933 $         |   |   | 13,892      |   | $ | 573          |  
|Cost
      of goods sold                    |   | (104,221         | ) |   | (1,287      | ) |   | (19,064      | )
|                                            |   |                  |   |   |             |   |   |              |  
|Gross
      margin                          |   | (76,288          | ) |   | 12,605      |   |   | (18,491      | )
|                                            |   |                  |   |   |             |   |   |              |  
|EXPENSES                                    |   |                  |   |   |             |   |   |              |  
|Amortization                                |   | 5,977            |   |   | 1,282       |   |   | 2,514        |  
|Professional fees                           |   | 374,588          |   |   | 109,883     |   |   | 27,753       |  
|Management fees                             |   | 30,880           |   |   | 6,905       |   |   | 3,735        |  
|Marketing expenses                          |   | 2,660,238        |   |   | 766,346     |   |   | 327,611      |  
|Other operating expenses                    |   | 722,779          |   |   | 213,733     |   |   | 169,953      |  
|Foreign
      currency loss                 |   | 21,818           |   |   | 21,818      |   |   | -            |  
|                                            |   |                  |   |   |             |   |   |              |  
|Total
      expenses                        |   | 3,816,280        |   |   | 1,119,967   |   |   | 531,566      |  
|                                            |   |                  |   |   |             |   |   |              |  
|LOSS BEFORE OTHER ITEMS, EXTRAORDINARY ITEM |   |                  |   |   |             |   |   |              |  
|AND INCOME TAXES                            |   | (3,892,568       | ) |   | (1,107,362  | ) |   | (550,057     | )
|                                            |   |                  |   |   |             |   |   |              |  
|Interest income                             |   | 32,147           |   |   | -           |   |   | 14,146       |  
|Interest expense                            |   | (43,295          | ) |   | (1,315      | ) |   | (18,798      | )
|Other income                                |   | 2,315            |   |   | -           |   |   | -            |  
|Gain
      on settlement of debt            |   | 770,382          |   |   | -           |   |   | -            |  
|                                            |   |                  |   |   |             |   |   |              |  
|LOSS BEFORE INCOME TAXES                    |   | (3,131,019       | ) |   | (1,108,677  | ) |   | (554,709     | )
|                                            |   |                  |   |   |             |   |   |              |  
|Provision
      for income taxes            |   | 6                |   |   | -           |   |   | 6            |  
|                                            |   |                  |   |   |             |   |   |              |  
|NET LOSS                                    |   | (3,131,025       | ) |   | (1,108,677  | ) |   | (554,715     | )
|                                            |   |                  |   |   |             |   |   |              |  
|OTHER COMPREHENSIVE LOSS                    |   |                  |   |   |             |   |   |              |  
|Foreign currency translation adjustment     |   | (232,005         | ) |   | (183,106    | ) |   | (34,279      | )
|                                            |   |                  |   |   |             |   |   |              |  
|COMPREHENSIVE LOSS                          | $ | (3,363,030       | ) | $ | (1,291,783  | ) | $ | 588,994      |  
|                                            |   |                  |   |   |             |   |   |              |  
|                                            |   |                  |   |   |             |   |   |              |  
|BASIC AND DILUTED
      NET LOSS PER SHARE  |   |                  |   | $ | (0.01       | ) | $ | (0.01        | )
|                                            |   |                  |   |   |             |   |   |              |  
|WEIGHTED AVERAGE NUMBER OF                  |   |                  |   |   |             |   |   |              |  
|COMMON SHARES OUTSTANDING                   |   |                  |   |   | 104,692,156 |   |   | 75,875,000   |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-3

---

VITAVEA INC.
  (formerly GA Computer Sciences Inc.)
  (A Development Stage Company) CONSOLIDATED STATEMENTS OF CASH FLOWS
  (Expressed in U.S. Dollars)
  (Unaudited)

|                                                                                        |   | Cumulative       |   |   |             |   |   |              |  
|--------------------------------------------------------------------------------------- | - | ---------------- | - | - | ----------- | - | - | ------------ | -
|                                                                                        |   | Amounts          |   |   | Three       |   |   | Three        |  
|                                                                                        |   | From Inception   |   |   | Months      |   |   | Months       |  
|                                                                                        |   | (March 31, 2004) |   |   | Ended       |   |   | Ended        |  
|                                                                                        |   | to January 31,   |   |   | January 31, |   |   | December 31, |  
|                                                                                        |   | 2007             |   |   | 2007        |   |   | 2005         |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|CASH FLOWS FROM OPERATING ACTIVITIES                                                    |   |                  |   |   |             |   |   |              |  
|Net loss for the period                                                                 | $ | (3,901,401       | ) | $ | (1,108,677  | ) | $ | (554,715     | )
|Adjustments to reconcile net income to cash used
      in development stage activities: |   |                  |   |   |             |   |  
|Amortization                                                                            |   | 5,977            |   |   | 1,282       |   |   | 2,514        |  
|Gain on settlement of debt                                                              |   | 770,382          |   |   | -           |   |   | -            |  
|Additional paid-in capital                                                              |   | 1,240,459        |   |   | -           |   |   | -            |  
|Impairment loss on inventories                                                          |   | 96,225           |   |   | -           |   |   | -            |  
|Change in operating assets and liabilities                                              |   |                  |   |   |             |   |   |              |  
|Increase in other receivables                                                           |   | (322,638         | ) |   | (245,953    | ) |   | (76,685      | )
|Increase in inventory                                                                   |   | (490,259         | ) |   | (490,259    | ) |   | -            |  
|Increase in prepaid expenses                                                            |   | (6,197           | ) |   | (390,677    | ) |   | (97          | )
|Increase in assets not
      allocated to investing or financing activities             |   | (119,664         | ) |   | -           |   |   | -            |  
|Increase in accounts payable and accrued
      liabilities                              |   | 1,242,301        |   |   | 954,383     |   |   | 123,418      |  
|Increase in accrued interest payable                                                    |   | 20,113           |   |   | 1,315       |   |   | 18,798       |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|Net cash used in operating activities                                                   |   | (1,464,702       | ) |   | (887,909    | ) |   | (486,767     | )
|                                                                                        |   |                  |   |   |             |   |   |              |  
|CASH FLOWS FROM INVESTING ACTIVITIES                                                    |   |                  |   |   |             |   |   |              |  
|Acquisition of equipment                                                                |   | (3,079           | ) |   | -           |   |   | 796          |  
|Acquisition of patent                                                                   |   | (29,655          | ) |   | -           |   |   | 29,655       |  
|Acquisition
      of MEBA & Baur –deferred                                              |   | (1,216,116       | ) |   | (390,677    | ) |   |              |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|Net
      cash used in investing activities                                             |   | (1,248,850       | ) |   | (390,677    | ) |   | 30,451       |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|CASH FLOWS FROM FINANCING ACTIVITIES                                                    |   |                  |   |   |             |   |   |              |  
|Cash acquired from Vitavea Inc.                                                         |   | 39,982           |   |   | 39,982      |   |   | -            |  
|Issuance of capital stock for cash                                                      |   | 1,258,415        |   |   | 1,190,065   |   |   | -            |  
|Proceeds from loan receivable                                                           |   | -                |   |   |             |   |   | 74,439       |  
|Proceeds
      from loans payable                                                       |   | 1,538,056        |   |   | 121,065     |   |   | 1,158,909    |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|Net
      cash provided by financing activities                                         |   | 2,836,453        |   |   | 1,351,112   |   |   | 1,233,348    |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|EFFECT OF FOREIGN CURRENCY TRANSLATION ON                                               |   |                  |   |   |             |   |   |              |  
|CASH AND CASH EQUIVALENTS
      DURING THE PERIOD                                       |   | (71,033          | ) |   | (22,127     | ) |   | (103,007     | )
|                                                                                        |   |                  |   |   |             |   |   |              |  
|NET INCREASE IN CASH                                                                    |   | 51,868           |   |   | 50,399      |   |   | 674,025      |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|CASH AND CASH EQUIVALENTS,
      BEGINNING OF PERIOD                                    |   | -                |   |   | 1,469       |   |   | 146,436      |  
|                                                                                        |   |                  |   |   |             |   |   |              |  
|CASH AND CASH EQUIVALENTS,
      END OF PERIOD                                          | $ | 51,868           |   | $ | 51,868      |   | $ | 1,153,461    |  

The accompanying notes are an integral part of these consolidated
  financial statements.

F-4

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|1. | HISTORY AND ORGANIZATION OF THE COMPANY
|-- | ---------------------------------------

Vitavea Inc. (formerly GA Computer Sciences
  Inc.) (the Company) was incorporated on March 10, 2004, under the
  Laws of the State of Nevada and was engaged in the business of producing, marketing
  and selling software created by Open Office in pre-packaged, shrink-wrapped
  standard compact disk jewel cases via the internet through the Companys
  website. Effective November 13, 2006, the Company acquired 100% of the issued
  and outstanding shares of Vitavea AG (Vitavea), a company engaged
  in the business of manufacturing, marketing and distributing nutritional supplements.
  The Company has abandoned its software business in order to focus its resources
  on the development of Vitaveas nutritional supplement business. The Company
  is considered to be a development stage company, as it has not generated significant
  revenues from operations.

Effective November 13, 2006, the Company
  acquired 100% of the issued and outstanding shares of Vitavea from WKB Beteiligungsgesellschaft
  mbH (WKB) and Crystalwood Holdings Inc. (Crystalwood)
  in exchange for Euro 300,000 and an aggregate of 34,350,000 shares of the Companys
  common stock. In addition, Peter Hoyle and Lina Zhou transferred an aggregate
  of 40,650,000 shares of the Companys common stock already issued and outstanding
  prior to the transaction to WKB in exchange for $10,000. Completion of the acquisition
  resulted in the former shareholders of Vitavea holding the majority of the Companys
  issued and outstanding common stock. As a result, the transaction was accounted
  for as a recapitalization of Vitavea.

The unaudited consolidated financial
  statements of the Company prior to November 13, 2006 are those of Vitavea. The
  Companys date of incorporation is considered to be March 31, 2004, the
  date of inception of Vitavea AG. Effective November 27, 2006, the Company changed
  its name from GA Computer Sciences Inc. to Vitavea Inc.

Effective March 31, 2006, Vitavea changed
  its year-end from December 31 to October 31 to correspond with the Companys
  year-end. Comparative financial information for the three months ended December
  31, 2005 has been included in these unaudited financial statements.

These unaudited financial statements
  have been prepared in conformity with generally accepted accounting principles
  in the United States of America for interim financial information. The accompanying
  consolidated financial statements do not include all information and footnote
  disclosures required for an annual set of financial statements prepared under
  United States of America generally accepted accounting principles. In the opinion
  of management, all adjustments (consisting solely of normal recurring accruals)
  considered necessary for a fair presentation of financial position, results
  of operations and cash flows as at January 31, 2007 and for all periods presented,
  have been included. Interim results for the period ended January 31, 2007 are
  not necessarily indicative of the results that may be expected for the fiscal
  year as a whole.

F-5

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|2. | GOING CONCERN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | These consolidated financial statements have
        been prepared with the on-going assumption that the Company will be able
        to realize its assets and discharge its liabilities in the normal course
        of business. However, certain conditions noted below raise substantial
        doubt about the Companys ability to continue as a going concern.
        These financial statements do not include any adjustments to the amounts
        and classifications of assets and liabilities that might be necessary
        should the Company be unable to continue as a going concern.                                                                                                                                                    
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | The operations of the Company have primarily
        been funded by the sale of common stock and loans received. Continued
        operations of the Company are dependent on the Companys ability
        to complete equity financings or generate profitable operations in the
        future. Managements plan in this regard is to secure additional
        funds through future equity financings. Such financings may not be available
        or may not be available on reasonable terms to the Company.                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|3. | SIGNIFICANT ACCOUNTING POLICIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | The financial statements of the Company have
        been prepared in conformity with generally accepted accounting principles
        in the United States of America and are stated in US dollars. The significant
        accounting policies adopted by the Company are as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | The preparation of financial statements in
        conformity with generally accepted accounting principles in the United
        States requires management to make estimates and assumptions that affect
        the reported amount of assets and liabilities and the disclosure of contingent
        assets and liabilities at the date of the financial statements and the
        reported amount of revenues and expenses during the reporting period.
        Actual results could differ from these estimates.                                                                                                                                                                                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | The functional currency of the Company is
        the United States dollar. The Companys subsidiary, Vitavea AG, uses
        the Euro as its functional currency. Accordingly, monetary assets and
        liabilities denominated in a foreign currency are translated at the exchange
        rate in effect at the balance sheet date while non-monetary assets and
        liabilities are translated at historical rates. Revenue and expense items
        denominated in a foreign currency are translated at exchange rates prevailing
        when such items are recognized in the statement of operations. Exchange
        gains and losses arising on translation of foreign currency items are
        included in the statement of operations.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   | The Company follows the current rate method
        of translation with respect to its foreign subsidiary. Accordingly, assets
        and liabilities are translated into U.S. dollars at the period-end exchange
        rates while revenue and expenses are translated at the average exchange
        rates during the period. Related exchange gains and losses are included
        in a separate component of stockholders equity as accumulated other
        comprehensive income.                                                                                                                                                                                                                                                                  

F-6

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | The Company considers cash held at banks and
        all highly liquid investments with original maturities of three months
        or less to be cash and cash equivalents.                                                                                                                                                                                                                                                                                                                                                                                                                      
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Inventory is valued at the lower of cost and
        net realizable value. Cost is determined on a first-in-first-out basis.
        Inventories consist of nutritional supplements and are all finished goods.                                                                                                                                                                                                                                                                                                                                                                                   
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (e)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Prepaid expenses consist primarily of a refundable
        vehicle lease deposit.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (f)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Other receivables consist primarily of Value
        Added Tax in Germany.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (g)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Equipment is recorded at cost and consists
        of computer equipment. Depreciation is calculated using the straight-line
        method over the useful lives of the assets. Maintenance and repairs are
        expensed as incurred while betterments or renewals are capitalized. Computer
        equipment is amortized over the estimated useful life of three years.                                                                                                                                                                                                                   
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (h)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Patents are recorded at cost. Capitalized
        amounts relate solely to the acquisition of one patent. Depreciation is
        calculated using the straight-line method over the useful life of the
        patent of eight years.                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (i)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | The Company has adopted Statement of Financial
        Accounting Standards (SFAS) 142, Goodwill and Intangible
        Assets, which requires that costs of internally developing, maintaining
        or restoring intangible assets that are not specifically identifiable,
        that have indeterminate lives, or that are inherent in a continuing business
        and related to an entity as a whole, be recognized as an expense when
        incurred. Goodwill and intangible assets acquired for fair value having
        definite lives are amortized over their useful life.

F-7

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | (j)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | The Company reviews all long-lived assets
        for impairment whenever events or changes in circumstances indicate that
        the carrying amount of an asset may not be recoverable. Recoverability
        of assets to be held and used is measured by a comparison of the carrying
        amount of an asset to future net cash flows expected to be generated by
        the asset. If such assets are considered to be impaired, the impairment
        recognized is measured by the amount by which the carrying amount of the
        assets exceeds the fair value of the assets. Assets to be disposed of
        are reported at the lower of the carrying amount or fair value less costs
        to sell.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | (k)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | The Company recognizes product revenue when
        persuasive evidence of an arrangement exists, delivery has occurred, the
        sales price is fixed or determinable and collectibility is reasonably
        assured. Revenue from products is recognized when title passes to the
        customer and all revenue recognition criteria specified above is met.                                                                                                                                                                                                                                                                                                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | (l)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | A deferred tax asset or liability is recorded
        for all temporary differences between financial and tax reporting and
        net operating loss carryforwards. Deferred tax expenses (benefit) result
        from the net change during the period of deferred tax assets and liabilities.                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | Deferred tax assets are reduced by a valuation
        allowance when, in the opinion of management, it is more likely than not
        that some portion or all of the deferred tax assets will not be realized.
        Deferred tax assets and liabilities are adjusted for the effects of changes
        in tax laws and rates on the date of enactment.                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | (m)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | The Company's financial instruments consist
        of cash and cash equivalents, other receivables, accounts payable and
        accrued liabilities and loans payable. Unless otherwise noted, it is management's
        opinion that the Company is not exposed to significant interest, currency
        or credit risks arising from these financial instruments. The fair value
        of these financial instruments approximates their carrying values, unless
        otherwise noted.                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   | The Company accounts for stock-based compensation
        issued to employees in accordance with the provisions of SFAS 123R, Share-Based
        Payment.which superseded Accounting Principles Board (APB)
        Opinion 25, Accounting for Stock Issued to Employees.                                                                                                                                                                                                                                                                                                                                                                                                                                             

F-8

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | The Company accounts for stock-based compensation
        issued to non-employees in accordance with the provisions of SFAS 123,
        Accounting for Stock-Based Compensation,and the consensus
        in Emerging Issues Task Force (EITF) No. 96-18, Accounting
        for Equity Instruments that are Issued to Other Than Employees for Acquiring
        or in Conjunction with Selling, Goods or Services.                                                                       
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | As of January 31, 2007, there were no stock
        options granted.                                                                                                                                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (o)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Basic net loss per share is computed by dividing
        the net loss for the period by the weighted average number of shares of
        common stock outstanding during the period. Diluted earnings per share
        takes into consideration shares of common stock outstanding (computed
        under basic earnings per share) and potentially dilutive shares of common
        stock. As of January 31, 2007 and 2006, there were no potentially dilutive
        securities outstanding.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (p)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | The Company has adopted SFAS 130, Reporting
        of Comprehensive Income,which establishes guidelines for the
        reporting and display of comprehensive income (loss) and its components
        in financial statements. Comprehensive income (loss) includes foreign
        currency translation adjustments.                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (q)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | The Company is a development stage company
        as defined in SFAS 7, Accounting and Reporting by Development
        Stage Enterprises,as it is devoting substantially all of its
        efforts to establish a new business and planned principal operations have
        not yet commenced.                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (r)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Cash and cash equivalents is the only financial
        instrument that potentially subjects the Company to concentration of credit
        risk. The Company maintains cash in bank accounts that, at times, may
        exceed federally insured limits. The Company has not experienced any losses
        in such accounts and believes it is not exposed to any significant risks
        on its cash in bank accounts.                                                                      

F-9

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|3. | SIGNIFICANT ACCOUNTING POLICIES (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | (s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | In July 2006, the Financial Accounting Standards
        Board (FASB) issued FASB Interpretation No. (FIN)
        48, Accounting for Uncertainty in Income Taxes. FIN
        48 clarifies the accounting and reporting for uncertainties in income
        tax law. FIN 48 prescribes a comprehensive model for the financial statement
        recognition, measurement, presentation, and disclosure of uncertain tax
        positions taken or expected to be taken in income tax returns. FIN 48
        is effective for fiscal years beginning after December 15, 2006.                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | In September 2006, the SEC issued Staff Accounting
        Bulletin (SAB) No. 108, Considering the Effects of
        Prior Year Misstatements when Quantifying Misstatements in Current Year
        Financial Statements. SAB No. 108 provides guidance on how prior
        year misstatements should be taken into consideration when quantifying
        misstatements in current year financial statements for purposes of determining
        whether the current years financial statements are materially misstated.
        SAB No. 108 is effective for fiscal years ending on or after November
        15, 2006.                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | In September 2006, the FASB issued SFAS No.
        157, Fair Value Measurements.SFAS No. 157 establishes
        a framework for measuring the fair value of assets and liabilities. This
        framework is intended to provide increased consistency in how fair value
        determinations are made under various existing accounting standards which
        permit, or in some cases require, estimates of fair market value. SFAS
        No. 157 is effective for fiscal years beginning after November 15, 2007,
        and interim periods within those fiscal years. Earlier application is
        encouraged, provided that the reporting entity has not yet issued financial
        statements for that fiscal year, including any financial statements for
        an interim period within that fiscal year.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | The Company does not expect that the adoption
        of these new accounting pronouncements will have a significant effect
        on its financial statements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | (t)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   | Certain amounts reported in the prior periods
        have been reclassified to conform to the current periods presentation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

F-10

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|3. | DEFERRED ACQUSITION COSTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | On November 28, 2006, Vitavea entered into
        an agreement to acquire 100% of the issued and outstanding shares of two
        companies, Adolf Baur GmbH (Baur) and MEBA Medizinische Badebetriebsgesellschaft
        mbH (MEBA) for an aggregate purchase price of Euro 2,250,000
        (approximately US -$2,857,500) of which a total of Euro 950,000 (US -$1,216,117)
        has already been paid. Baur and MEBA are companies engaged in the business
        of manufacturing and distributing medicinal mineral bath products. The
        remaining amount of the purchase price, with interest payable thereon,
        is due as follows:
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (i)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (ii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (iii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | (iv)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|4. | EQUIPMENT AND PATENTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|   | Equipment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

| |                          |   | January 31, |  
| | ------------------------ | - | ----------- | -
| |                          |   | 2007        |  
| |                          |   |             |  
| | Computer equipment       |   | 3,079       |  
| | Accumulated depreciation |   | (1,156      | )
| |                          |   |             |  
| | Net book value           | $ | 1,923       |  

F-11

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|4. | EQUIPMENT AND PATENTS (continued) Patent
|-- | ----------------------------------------

| |                          |   | January 31, |  
| | ------------------------ | - | ----------- | -
| |                          |   | 2007        |  
| |                          |   |             |  
| | Patent                   | $ | 29,655      |  
| | Accumulated depreciation |   | (4,821      | )
| |                          |   |             |  
| | Net book value           | $ | 24,834      |  

|   | In the event that facts and circumstances indicate that
        the carrying amount of an asset may not be recoverable and an estimate
        of future undiscounted cash flows is less than the carrying amount of
        the asset, an impairment loss will be recognized. Management's estimates
        of revenues, operating expenses, and operating capital are subject to
        certain risks and uncertainties which may affect the recoverability of
        the Company's investments in its assets. Although management has made
        its best estimate of these factors based on current conditions, it is
        possible that changes could occur which could adversely affect management's
        estimate of the net cash flow expected to be generated from its operations.
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|5. | LOANS PAYABLE - CURRENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   | During the three months ended January 31, 2007, several
        loans were granted from a third party individual totaling Euro 170,000
        (US -$220,320) of which Euro 125,000 (US -$162,000) was repaid in the
        same period. The loans are non-interest bearing and have no specific terms
        for repayment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   | During the year ended October 31, 2006, a loan was granted
        from a third party company for $75,000. The loan bears interest at 8%
        per annum, compounded annually, and was due November 16, 2006. During
        the three months ended January 31, 2007, the third party company agreed
        to extend the term of the loan until November 17, 2007. Interest expense
        accrued for the three months ended January 31, 2007 totaled $1,315.                                                                                                                                                                                                                                                                                                                                   
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|6. | RELATED PARTY TRANSACTIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   | Loans Payable Current                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
|   | During the year ended October 31, 2006, a loan was granted
        from a director and officer of the Company and managing director of Vitavea
        for Euro 13,000 (US -$16,848). During the three months ended January,
        31, 2007, a second loan was granted for Euro 48,000 (US -$62,208). The
        loans are non-interest bearing and have no specific terms for repayment.                                                                                                                                                                                                                                                                                                                                                                                                          

F-12

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|6. | RELATED PARTY TRANSACTIONS (continued)
|-- | --------------------------------------

Other

At January 31, 2007, included in accounts
  payable and accrued liabilities is Euro 9,340 (US -$12,105) owed to a company
  with a common managing director of the Company for office rent. Office rent
  expense totaled Euro 6,000 (US -$7,811) for the three months ended January 31,
  2007.

At January 31, 2007, included in accounts
  payable and accrued liabilities is Euro 1,000 (US -$1,296) owed to a managing
  director of Vitavea for management fees.

Management and consulting fees paid to
  officers and directors of the Company and the managing director of Vitavea for
  the three months ended January 31, 2007 totaled $6,905. Amounts due to and from
  officers and directors are unsecured, non-interest bearing and due on demand.

|7. | COMMON STOCK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | The Companys articles of incorporation allow it
        to issue up to 750,000,000 shares of common stock, par value $0.001. Effective
        January 17, 2006, the Company effected a stock split of its common stock
        by issuing ten new shares for each old share. Except as otherwise stated
        to the contrary in these financial statements, all references to shares
        and prices per shares have been adjusted to give retroactive effect to
        the stock split.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | On March 31, 2004, the Company issued 74,775,308 shares
        of common stock for total proceeds of Euro 50,000 (US -$68,350).                                                                                                                                                                                                                                                                                                                                                                 
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | On November 13, 2006, the Company acquired all the issued
        and outstanding stock of Vitavea, which was accounted for as a recapitalization
        of the Company (Note 1) in exchange for 34,350,000 shares of common stock.
        The issued number of shares of common stock is that of the Company with
        adjustments made for differences in par value between the Company and
        Vitavea AG.                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | On December 11, 2006, the Company issued 500,000 common
        shares at a price of Euro 1.00 (US -$1.33) per share for total proceeds
        of Euro 500,000 (US -$664,717) in a private placement transaction.                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | On December 29, 2006, the Company issued 400,000 common
        shares at a price of Euro 1.00 (US -$1.31) per share for total proceeds
        of Euro 400,000 (US -$525,348) in a private placement transaction.                                                                                                                                                                                                                                                                               
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|8. | SEGMENT INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   | The Companys operations following the acquisition
        of Vitavea AG were conducted in one reportable segment, being the development
        of Vitaveas nutritional supplement business. The Companys
        equipment and patent are located in Germany.                                                                                                                                                                                                                                

F-13

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|9.  | COMMITMENTS                                                                                                                                                                                                                                                                                                                                              
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                          
|    | On August 1, 2005, Vitavea AG entered into a lease agreement
        with a company with a common managing director for tenancy of office space.
        The lease agreement requires monthly lease payments of Euro 2,000 (US
        -$2,592) plus taxes.                                                                                              
|    |                                                                                                                                                                                                                                                                                                                                                          
|    | On April 27, 2004, Vitavea entered into a vehicle lease
        agreement that expires on May 1, 2008. The vehicle lease agreement required
        an initial payment of Euro 4,900 (US -$6,350) plus taxes and requires
        monthly lease payments of Euro 276 (US -$358) plus taxes. The deposit
        will be refunded at the end of the lease.
|    |                                                                                                                                                                                                                                                                                                                                                          
|10. | SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS                                                                                                                                                                                                                                                                                                       

| |                |   | Cumulative   |  |   |              |  |   |              | 
| | -------------- | - | ------------ |  | - | ------------ |  | - | ------------ | 
| |                |   | Amounts from |  |   |              |  |   |              | 
| |                |   | Inception    |  |   |              |  |   |              | 
| |                |   | (March 31,   |  |   | Three Months |  |   | Three Months | 
| |                |   | 2004) to     |  |   | Ended        |  |   | Ended        | 
| |                |   | January 31,  |  |   | January, 31  |  |   | December, 31 | 
| |                |   | 2007         |  |   | 2007         |  |   | 2005         | 
| |                |   |              |  |   |              |  |   |              | 
| | Cash paid for: |   |              |  |   |              |  |   |              | 
| | Interest       | $ | 5,036        |  | $ | -            |  | $ | -            | 
| | Income taxes   | $ | 6            |  | $ | -            |  | $ | 6            | 
| |                |   |              |  |   |              |  |   |              | 
| |                |   |              |  |   |              |  |   |              | 

Non-cash Transaction

Investing and financing activities that
  do not have an impact on current cash flows are excluded from the statement
  of cash flows.

During the period from inception (March
  31, 2004) to January 31, 2007, the Company issued 34,350,000 common shares for
  the acquisition of Vitavea AG.

During the period ended October 31, 2006,
  WKB agreed to waive its claim of Euro 1,578,000 (US -$2,029,655). A portion
  of the claim valued at Euro 974,767 (US -$1,240,459) was transferred into additional
  paid-in capital. The remaining portion, including accumulated interest totaling
  Euro 15,101 (US -$18,814) was recorded as a gain on settlement of debt in the
  amount of Euro 618,334 (US -$770,382).

F-14

---

|VITAVEA INC.                                  
|----------------------------------------------
|(formerly GA Computer Sciences Inc.)          
|(A Development Stage Company)                 
|NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
|(Expressed in U.S. Dollars)                   
|January 31, 2007                              
|(Unaudited)                                   
|                                              

|11. | SUBSEQUENT EVENTS
|--- | -----------------

On February 5, 2007, the Company issued
  260,416 units at a price of Euro 0.96 (US -$1.24) per unit in a private placement
  transaction. Each unit consists of one share of the Companys common stock
  and one share purchase warrant for total proceeds of Euro 250,000 (US -$324,002).
  Each warrant entitles the holder to purchase an additional share of the Companys
  common stock at a price of Euro 0.96 (US -$1.24) per share for a period of one
  year from the date of closing.

On February 14, 2007, the Company issued
  150,000 units at a price of Euro 1.00 (US -$1.30) per unit in a private placement
  transaction. Each unit consists of one share of the Companys common stock
  and one share purchase warrant for total proceeds of Euro 150,000 (US -$194,401).
  Each warrant entitles the holder to purchase an additional share of the Companys
  common stock at a price of Euro 1.00 (US -$1.30) per share for a period of one
  year from the date of closing.

On March 12, 2007, the Company issued
  537,634 common shares at a price of Euro 0.93 (US -$1.21) per share for total
  proceeds of Euro 500,000 (US -$648,004) in a private placement transaction.

F-15

---

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF
OPERATION.

Cautionary Statement Regarding Forward-Looking
Statements

Certain statements contained in this Quarterly Report
constitute "forward-looking statements. These statements, identified by words
such as plan, "anticipate," "believe," "estimate," "should," "expect" and
similar expressions include our expectations and objectives regarding our future
financial position, operating results and business strategy. These statements
reflect the current views of management with respect to future events and are
subject to risks, uncertainties and other factors that may cause our actual
results, performance or achievements, or industry results, to be materially
different from those described in the forward-looking statements. Such risks and
uncertainties include those set forth under the caption "Management's Discussion
and Analysis or Plan of Operation" and elsewhere in this Quarterly Report. We
advise you to carefully review the reports and documents we file from time to
time with the United States Securities and Exchange Commission (the SEC),
particularly our Annual Reports on Form 10-KSB and our Current Reports on Form
8-K.

As used in this Quarterly Report, the terms "we, "us, "our,
the Company and Vitavea mean Vitavea Inc. and its subsidiaries, unless
otherwise indicated. All dollar amounts in this Quarterly Report are in U.S.
dollars unless otherwise indicated.

CORPORATE BACKGROUND

We were incorporated on March 10, 2004 under the laws of the
State of Nevada.

Effective November 13, 2006, we completed the acquisition of a
100% ownership interest of Vitavea AG. The acquisition of Vitavea AG was
completed pursuant to the terms of the share purchase agreement dated effective
as of July 31, 2006 (the Share Purchase Agreement) among us, Vitavea AG, WKB
Beteiligungsgesellschaft mbH (WKB), Crystalwood Holdings Ltd. (Crystalwood),
Peter J. Hoyle and Lina Zhou.

Under the terms of the Share Purchase Agreement, we acquired
all of the outstanding shares of Vitavea AG from WKB and Crystalwood and, in
exchange, we issued the following shares of our common stock:

|                                 |  | Shares of Vitavea AG |  |  | Shares of         | 
|-------------------------------- |  | -------------------- |  |  | ----------------- | 
|                                 |  | Acquired             |  |  | Our Common Stock  | 
|                                 |  |                      |  |  | Issued            | 
|WKB Beteiligungsgesellschaft mbH |  | 45,500               |  |  | 31,258,500        | 
|Crystalwood Holdings Ltd.        |  | 4,500                |  |  | 3,091,500         | 
|Total:                           |  | 50,000 shares        |  |  | 34,350,000 shares | 

Also, WKB acquired an additional 40,650,000 shares of our
common stock from Mr. Hoyle and Ms. Zhou at an aggregate price of $10,000 in
accordance with the terms of the Share Purchase Agreement.

Prior to acquiring Vitavea, we had been engaged in the business
of producing, marketing and selling OpenOffice computer software on CD-ROM. We
produced CD-ROMs of OpenOffice

3

---

software and marketed and sold the discs via the Internet,
through our website at www.gacompsi.com. Now that we have acquired all of the
outstanding shares of Vitavea, we have discontinued our software business in
order to focus our resources on developing Vitaveas nutritional supplements
business.

VITAVEA AG

Vitavea AG was formed on March 31, 2004 under the laws of the
Federal Republic of Germany. Vitavea AG is engaged in the business of marketing
and distributing nutritional supplements.

Currently, Vitavea AG is focusing on marketing three
nutritional supplements that it calls MENTAL VIT, MENTAL VIT Junior and Oliva
Vital.

In addition, Vitavea AG holds a patent for a chemical
composition that it hopes to be able to develop into an approved drug to be used
to assist in the maintenance of blood sugar levels. Vitavea AG hopes to begin
the drug approval process sometime in 2007.

Mental Vit and Mental Vit Junior

Vitavea AG has developed two nutritional supplements called
MENTAL VIT and MENTAL VIT Junior that it intends to sell in Germany.

Vitavea AG has developed MENTAL VIT and MENTAL VIT Junior to
provide a balanced combination of nutrients essential to a healthy body.
Vitamins, minerals and other trace elements play a vital role in maintaining a
healthy body. These substances are used by the body to convert food into energy,
to promote tissue and cell growth, to build and maintain the bodys immune
system, to produce vital hormones and enzymes, and to detoxify the body.
However, the human body is incapable of producing many of these vitamins,
minerals and trace elements on its own. In addition, although the variety of
foods available for consumption is greater than ever before, it is still
extremely difficult for people to maintain the proper nutritional balance
through choice of foods alone. MENTAL VIT and MENTAL VIT Junior are designed to
bridge this gap.

MENTAL VIT is a nutritional supplement containing 26 important
vitamins, minerals and trace elements, designed to meet a bodys needs. In
addition, MENTAL VIT provides a full daily dosage of important anti-oxidants and
carotenoids. MENTAL VIT is designed to deliver the body with key nutrients
essential to a healthy body. In addition, MENTAL VITs combination of key
nutrients can counteract the ageing process and increase mental and physical
functioning.

MENTAL VIT Junior is a special formulation designed by Vitavea
AG specifically for children and teenagers under the age of 16.

Oliva Vital

Oliva Vital is a nutritional supplement based upon oleuropein,
an olive oil extract found in the bark, roots, leaves and fruit of the olive
tree. This natural substance helps to make the olive tree resistant against
parasites and diseases. When ingested, oleuropein can act as a boost to the
bodys immune system, strengthening its ability to resist viruses and bacteria.
In addition, oleuropein can have an important antioxidant effect, shielding the
body against the damage caused by free radicals. Oliva Vital also contains
L-Carnitine, a substance that can assist the fat-burning process and help
promote the circulation of blood through the heart.

4

---

RECENT CORPORATE DEVELOPMENTS

The following significant developments have occurred since the
completion of our fiscal year ended October 31, 2006:

|1. | Effective November 13, 2006, we completed the acquisition
      of a 100% ownership interest of Vitavea AG. See Corporate Background
      above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|2. | On November 16, 2006, we entered into an amendment
      agreement to the loan agreement with Black Pointe Holdings Inc., pursuant
      to which Black Pointe Holdings Inc. agreed to extend the due date for the
      $75,000 loan granted to us from November 16, 2006 to November 16, 2007. A
      copy of the above amendment agreement to the loan agreement is attached as
      an exhibit to our Annual Report for the year ended October 31, 2006 filed
      with the SEC on February 13, 2007.                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|3. | Effective November 27, 2006, we changed our name from GA
      Computer Sciences Inc. to Vitavea Inc. in anticipation of completing
      the acquisition of Vitavea AG. Our symbol was changed to VVEA on
      November 27, 2006 upon completion of our name change to Vitavea
  Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|4. | On November 28, 2006, Vitavea AG entered into an
      agreement to acquire all of the shares of Adolf Baur GmbH and MEBA
      Medizinische Badebetriebsgesellschaft mbH. See Plan of Operation
      below.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|5. | On December 11, 2006, we completed a private placement
      for 500,000 shares of our common stock at a price of EUR 1.00
      (approximately $1.33) per share, for total proceeds of EUR 500,000
      (approximately $664,717). The subscribed for shares were sold in reliance
      on provisions of Regulation S under the Securities Act on the basis that
      the sole subscriber was not a US person as defined in Regulation S. No
      underwriting discounts or commissions were involved.                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|6. | On December 29, 2006, we completed a private placement
      for 400,000 shares of our common stock at a price of EUR 1.00
      (approximately $1.31) per share, for total proceeds of EUR 400,000
      (approximately $525,348). The subscribed for shares were sold in reliance
      on provisions of Regulation S under the Securities Act on the basis that
      the sole subscriber was not a US person as defined in Regulation S. No
      underwriting discounts or commissions were involved.                                                                                                                                                                                                                                                                                                              
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|7. | On February 5, 2007, we completed a private placement for
      260,416 units at a price of EUR 0.96 (approximately $1.25) per unit, for
      total proceeds of approximately EUR 250,000 (approximately $325,500). Each
      unit consists of one share of our common stock and one share purchase
      warrant, with each share purchase warrant entitling the holder to purchase
      one additional share of our common stock at a price of EUR 0.96 per share
      for a period of one year from the date the warrant was issued. The
      subscribed for shares were sold in reliance on the provisions of
      Regulation S under the Securities Act on the basis that each subscriber
      was not a US person as defined in Regulation S. No underwriting discounts
      or commissions were involved.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|8. | On February 14, 2007, we completed a private placement
      for 150,000 units at a price of EUR 1.00 (approximately $1.30) per unit,
      for total proceeds of approximately EUR 150,000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

5

---

|   | (approximately $195,000). Each unit consists of one share
      of our common stock and one share purchase warrant, with each share
      purchase warrant entitling the holder to purchase one additional share of
      our common stock at a price of EUR 1.00 per share for a period of one year
      from the date the warrant was issued. The subscribed for shares were sold
      in reliance on the provisions of Regulation S under the Securities Act on
      the basis that each subscriber was not a US person as defined in
      Regulation S. No underwriting discounts or commissions were
    involved.
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|9. | On March 12, 2007, we completed a private placement for
      537,634 shares of our common stock at a price of EUR 0.93 (approximately
      $1.21) per share, for total proceeds of EUR 500,000 (approximately
      $650,000). The subscribed for shares were sold in reliance on provisions
      of Regulation S under the Securities Act of 1933 (the Securities Act) on
      the basis that the sole subscriber was not a US person as defined in
      Regulation S. No underwriting discounts or commissions were
    involved.                                                                                 

PLAN OF OPERATION

Our plan of operation for the next twelve months will involve
the following:

|(a) | Product Marketing Efforts: During the next twelve
      months, Vitavea AG will attempt to develop the market for its MENTAL VIT,
      MENTAL VIT Junior and Oliva Vital product lines. Vitavea AG will focus on
      marketing its products to local pharmacies and drug stores in Germany. In
      addition, Vitavea AG intends to launch a television advertising campaign
      on local television stations and a printed media campaign appearing in
      local magazines. Finally, Vitavea AG will explore the feasibility of
      direct marketing campaigns to be directed at German health and wellness
      centers.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|(b) | Product Development Efforts: Vitavea AG will begin
      product development efforts in order to expand its current product lines.
      Currently, Vitavea AG plans to work on developing a skin cream to be used
      for smoothing the skin and on developing a usable drug for maintaining
      blood sugar levels based on its chromium formulation. In addition, Vitavea
      AG is exploring the possibility of developing medical bath
  products.                                                                                                                                                                        

We anticipate that we will require approximately EUR 5,300,000
(approximately $6,890,000) over the next twelve months in order to complete
Vitavea AGs plan of operation. This amount will be spent on marketing and
advertising efforts, product development efforts and on general administrative
expenses related to the operation of our business.

In addition, we have entered into an agreement to acquire two
companies engaged in the business of manufacturing and distributing medicinal
mineral bath products. Over the next twelve months, we intend to proceed with
the acquisition of these companies, known as Adolf Baur GmbH (Baur) and MEBA
Medizinische Badebetriebsgesellschaft mbH (MEBA). The acquisition agreement
for Baur and MEBA calls for us to pay:

| | (i)   | EUR 250,000 (approximately $325,000) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before March 1, 2007;        
| | ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |       |                                                                                                                                                                     
| | (ii)  | EUR 250,000 (approximately $325,000) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before June 1, 2007;         
| |       |                                                                                                                                                                     
| | (iii) | EUR 250,000 (approximately $325,000) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before September 1, 2007; and

6

---

| | (iv) | EUR 550,000 (approximately $715,500) plus interest
      accrued at a rate of 6% per annum beginning on December 10, 2006, on or
      before December 1, 2007.
| | ---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------

As of the date of filing of this Quarterly Report, we had not
made the March 1, 2007 payment in respect of Baur and MEBA. We have withheld the
March payment because the principal and managing director of Baur and MEBA have
failed to provide us with full and open disclosure regarding the operations and
financial results of those companies on an ongoing basis. We intend to withhold
payment until Baur and MEBA provide us with satisfactory responses to our
inquiries. We are currently working to resolve this matter.

RESULTS OF OPERATIONS

Under generally accepted accounting principles, the acquisition
of Vitavea AG has been accounted for as a reverse takeover of Vitavea and
Vitavea AG has been treated as the acquiring entity for accounting and financial
reporting purposes. As such, our consolidated financial statements are presented
as a continuation of the operations of Vitavea AG and not Vitavea. The financial
information provided below for the period ended December 31, 2005 represents the
operations of Vitavea AG. The operations of Vitavea are included from the
effective date of the acquisition, November 13, 2006.

Vitavea AG changed its year-end from December 31 to October 31
prior to completion of the acquisition. As a result, comparative information to
the three months ended December 31, 2005 has been included in this Quarterly
Report.

First Quarter Summary

|                         |  | Three Months Ended |  |  | Three Months Ended |  |  | Percentage            | 
|------------------------ |  | ------------------ |  |  | ------------------ |  |  | --------------------- | 
|                         |  | January 31, 2007   |  |  | December 31, 2005  |  |  | Increase / (Decrease) | 
|Revenue                  |  | $13,892            |  |  | $573               |  |  | 2,324.4%              | 
|Costs of Goods Sold      |  | (1,287)            |  |  | (19,064)           |  |  | (93.2)%               | 
|Expenses                 |  | (1,119,967)        |  |  | (531,566)          |  |  | 110.7%                | 
|Interest Income          |  | -                  |  |  | 14,146             |  |  | (100)%                | 
|Interest Expense         |  | (1,315)            |  |  | (18,798)           |  |  | (93.0)%               | 
|Loss Before Income Taxes |  | $(1,108,677)       |  |  | $(554,709)         |  |  | 99.9%                 | 

Revenue

We have only earned nominal revenues to date and we do not
anticipate earning significant revenues in the near future.

Operating Expenses

Our expenses for the quarterly period ended January 31, 2007
and the quarterly period ended December 31, 2005 consisted of the following:

7

---

|                         |                    |  | Three Months      |  |                       | 
|------------------------ | ------------------ |  | ----------------- |  | --------------------- | 
|                         | Three Months Ended |  | Ended             |  | Percentage            | 
|                         | January 31, 2007   |  | December 31, 2005 |  | Increase / (Decrease) | 
|Amortization             | $1,282             |  | $2,514            |  | (49.0)%               | 
|Professional Fees        | 109,883            |  | 27,753            |  | 295.9%                | 
|Management Fees          | 6,905              |  | 3,735             |  | 84.9%                 | 
|Marketing Expenses       | 766,346            |  | 327,611           |  | 133.9%                | 
|Other Operating Expenses | 213,733            |  | 169,953           |  | 25.8%                 | 
|Foreign Currency Loss    | 21,818             |  | -                 |  | n/a                   | 
|Total                    | $1,119,967         |  | $531,566          |  | 110.7%                | 

Additional professional fees for the period ended January 31,
2007 include legal and accounting fees incurred by us and Vitavea AG in
connection with our acquisition of Vitavea AG and in respect of meeting our
ongoing reporting obligations under the Securities Exchange Act of 1934.
Marketing expenses increased by 133.9% during the period ended January 31, 2007.
This increase was largely a result of amounts spent for a television advertising
campaign for our products that is to air in Germany in February and March.

LIQUIDITY AND CAPITAL RESOURCES

|Working Capital           |                           |  |                            |  |                       | 
|------------------------- | ------------------------- |  | -------------------------- |  | --------------------- | 
|                          |                           |  |                            |  | Percentage            | 
|                          | At
      January 31, 2007 |  | At
      December 31, 2005 |  | Increase / (Decrease) | 
|Current Assets            | $2,107,437                |  | $1,278,623                 |  | 64.8%                 | 
|Current
      Liabilities | (1,508,254)               |  | (144,345)                  |  | 944.9%                | 
|Working Capital           | $599,183                  |  | $1,134,278                 |  | (47.2)%               | 

|Cash Flows                                                               |                  |  |                   | 
|------------------------------------------------------------------------ | ---------------- |  | ----------------- | 
|                                                                         | Three Months     |  | Three Months      | 
|                                                                         | Ended            |  | Ended             | 
|                                                                         | January 31, 2007 |  | December 31, 2005 | 
|Cash Flows Used In Operating Activities                                  | $(1,278,586)     |  | $(486,767)        | 
|Cash Flows Used In Investing Activities                                  | -                |  | 30,451            | 
|Cash Flows From Financing Activities                                     | 1,351,112        |  | 1,233,348         | 
|Net Increase in Cash (net of foreign currency translation
      effects) | $50,399          |  | $674,025          | 

The decrease in our working capital at January 31, 2007 from
December 31, 2005, and the increase in our cash used during the three months
ended January 31, 2007, is primarily a result of an increase in our marketing
expenses and professional fees, and from the fact that we earned nominal revenue
amounts during the three months ended January 31, 2007.

Future Financings

8

---

Currently, we do not have sufficient financial resources to
complete our plan of operation for the next twelve months and complete the
proposed acquisition of Baur and MEBA. We have not earned any significant
revenues to date, and there are no assurances that we will be able to generate
significant revenues in the future. As such, our ability to complete our plan of
operation is expected to be dependent upon our ability to obtain substantial
financing in the near term. To date, we have financed our operations through
sales of our equity securities and short-term loans. We have completed the
following financings since our fiscal year ended October 31, 2006:

|(a) | On December 11, 2006, we completed a private placement
      for 500,000 shares of our common stock at a price of EUR 1.00
      (approximately $1.33) per share, for total proceeds of EUR 500,000
      (approximately $664,717).                                                                                                                                                                                                                                                                                                         
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|(b) | On December 29, 2006, we completed a private placement
      for 400,000 shares of our common stock at a price of EUR 1.00
      (approximately $1.31) per share, for total proceeds of EUR 400,000
      (approximately $525,348).                                                                                                                                                                                                                                                                                                         
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|(c) | On February 5, 2007, we completed a private placement for
      260,416 units at a price of EUR 0.96 (approximately $1.25) per unit, for
      total proceeds of approximately EUR 250,000 (approximately $325,500). Each
      unit consists of one share of our common stock and one share purchase
      warrant, with each share purchase warrant entitling the holder to purchase
      one additional share of our common stock at a price of EUR 0.96 per share
      for a period of one year from the date the warrant was issued. 
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|(d) | On February 14, 2007, we completed a private placement
      for 150,000 units at a price of EUR 1.00 (approximately $1.30) per unit,
      for total proceeds of approximately EUR 150,000 (approximately $195,000).
      Each unit consists of one share of our common stock and one share purchase
      warrant, with each share purchase warrant entitling the holder to purchase
      one additional share of our common stock at a price of EUR 1.00 per share
      for a period of one year from the date the warrant was issued.
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|(e) | On March 12, 2007, we completed a private placement for
      537,634 shares of our common stock at a price of EUR 0.93 (approximately
      $1.21) per share, for total proceeds of EUR 500,000 (approximately
      $650,000).                                                                                                                                                                                                                                                                                                            

We anticipate that we will continue to rely on equity sales of
our common shares in order to continue to fund our business operations. If we
are successful in completing any equity financings, of which there is no
assurance, our existing shareholders will experience a dilution of their
interest in our company. If we are not successful in raising sufficient
financing, we will not be able to complete our current plan of operation. We do
not have any specific alternatives to our current plan of operation and have not
planned for any such contingency. If we are not successful in raising sufficient
financing, our business may fail and our shareholders may lose all or part of
their investment.

OFF-BALANCE SHEET ARRANGEMENTS

We have no significant off-balance sheet arrangements that have
or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of
operations, liquidity, capital expenditures or capital resources that is
material to stockholders.

9

---

CRITICAL ACCOUNTING POLICIES

The financial statements presented with this Quarterly Report
on Form 10-QSB have been prepared in accordance with generally accepted
accounting principles in the United States of America for interim financial
information. These financial statements do not include all information and
footnote disclosures required for an annual set of financial statements prepared
under United States generally accepted accounting principles. In the opinion of
our management, all adjustments (consisting solely of normal recurring accruals)
considered necessary for a fair presentation of the financial position, results
of operations and cash flows as at January 31, 2007 and for all periods
presented in the attached financial statements, have been included. Interim
results for the three month period ended January 31, 2007 are not necessarily
indicative of the results that may be expected for the fiscal year as a
whole.

Our significant accounting policies are described at Note 3 to
our financial statements for the three month period ended January 31, 2007.

RISKS AND UNCERTAINTIES

Need For Financing

We do not currently have the financial resources to complete
  our plan of operation for the next twelve months. We anticipate that we will
  require approximately $6,890,000 in financing in order to fund our plan of operation
  over the next twelve months, plus at least an additional $1,690,500 to fund
  the acquisition of Baur and MEBA. We presently do not have any financing arrangements
  in place and there is no assurance that we will be able to obtain sufficient
  financing on terms acceptable to us or at all. If further financing is not available
  or obtainable, our ability to meet our financial obligations and pursue our
  plan of operation will be substantially limited and investors may lose a substantial
  portion or all of their investment.

There Is A Risk That We May Not Complete The Acquisition Of
  Baur And MEBA

We have withheld payment of the amounts due under our agreement to acquire
  Baur and MEBA because the principal and managing director of those companies
  have failed to provide us with full and open disclosure about their current
  operations and financial results. We do not intend to advance additional payments
  under the acquisition agreement until we have received satisfactory responses
  to our inquiries. As a result, there is a significant risk that we will not
  complete the acquisition of Baur and MEBA, even if we have the financial resources
  to do so.

Limited Operating History, Risks Of A New Business
Venture

Vitavea AG was formed on March 31, 2004 and, as such, has a
very short operating history upon which future performance may be assessed.
Vitavea AG has only earned nominal revenues to date.

Potential investors should be aware of the difficulties
normally encountered by a new enterprise and the high rate of failure of such
enterprises. The potential for future success must be considered in light of the
problems, expenses, difficulties complications and delays encountered in
connection with the development of a business in the area in which we intend to
operate and in connection with the formation and commencement of operations of a
new business in general. These include, but are not limited to, unanticipated
problems relating to research and development programs, marketing, approvals by
government agencies, competition and additional costs and expenses that may
exceed current estimates. There is no history upon which to base any assumption
as to the likelihood that our business will prove successful, and there can be
no assurance that we will generate any operating revenues or ever achieve
profitable operations.

We May Become The Subject Of Product Liability Suits

We could become subject to product liability claims in
connection with the use of our nutritional supplements or any other future
products that we develop. If we do become the subject of such claims, we may not
have sufficient financial resources to defend against such claims or to
satisfy

10

---

any judgments made against us. We do not currently carry
product liability insurance and there are no assurances that we will carry such
insurance in the future. If we become the subject of such claims and are unable
to defend against such claims or are unsuccessful in defending against such
claims, our business may fail.

Nutritional Supplements Are Subject To Extensive Government
Regulation

The nutritional supplements industry is heavily regulated, and
those regulations are changing at a rapid pace. Although Vitavea AG has obtained
regulatory approval for its MENTAL VIT, MENTAL VIT Junior and Olivia Vital
products within Germany, there are no assurances that it will not be required to
obtain additional approvals in the future. In addition, if Vitavea AG is
successful in developing its chromium formulation or any other products, of
which there are no assurances, it will be required to obtain regulatory approval
for those products prior to bringing them to market. In order to obtain approval
for its products, Vitavea AG may be required to prove the effectiveness and
safety of its products. In addition, Vitavea AG could be required to conduct
lengthy and expensive clinical trials of its products. Obtaining regulatory
approval for Vitavea AGs products could be a lengthy and expensive process.
There are no assurances that Vitavea AG will be able to meet the future costs of
obtaining any necessary approvals or that Vitavea AG will be able to obtain such
approvals at all.

The Nutritional Supplements Industry Is Highly Competitive.
Many Of Our Competitors Are Better Established And Have Greater Resources Than
We Do

The nutritional supplements industry is highly competitive.
Many of our competitors are better established and have substantially greater
capital resources, research and development capabilities, and personnel
resources than we do. These companies may be better able than us to develop,
refine and manufacture new products and may be better able to market their
existing products. In addition, many of these competitors have products and
brand names with a high degree of customer awareness and customer loyalty. If we
are not able to overcome the competitive advantages possessed by our
competition, our business may fail.

Dependence On Key Personnel

Our future success will largely depend upon the performance of
our directors and officers and the managers of Vitavea AG. Our success will also
depend upon our ability to attract and retain skilled technical, research,
management, sales and marketing personnel. Competition for such personnel is
intense. The loss of key personnel or the inability to attract and retain key
personnel could have a significantly detrimental effect on our business,
operating results and financial condition.

ITEM 3. CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our
management, including our principal executive officer and principal financial
officer, we have evaluated the effectiveness of our disclosure controls and
procedures as required by Exchange Act Rule 13a-15(b) as of the end of the
period covered by this report. Based on that evaluation, our principal executive
officer and principal financial officer has concluded that these disclosure
controls and procedures are effective.

There were no changes in our internal control over financial
reporting during the last fiscal quarter that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.

11

---

PART II - OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS.

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS.

We completed two private placement financings during the month
of December, 2006 for total proceeds of approximately $1,190,065. A description
of these private placement financings is included in this Quarterly Report at
Item 2. Managements Discussion and Analysis or Plan of Operation, Recent
Corporate Developments.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS.

None.

ITEM 5.OTHER INFORMATION.

Unregistered Sales of Equity Securities

Since the end of our January 31, 2007 fiscal quarter, we have
completed three private placement financings:

| | (a) | a private placement financing completed on February 5,
      2007 for approximately $325,500;     
| | --- | --------------------------------------------------------------------------------------------------
| |     |                                                                                                   
| | (b) | a private placement financing completed on February 14,
      2007 for approximately $195,000; and
| |     |                                                                                                   
| | (c) | a private placement financing completed on March 12, 2007
      for approximately $650,000.       

A description of these private placement financings is included
  in this Quarterly Report at Item 2. Managements Discussion and Analysis
  or Plan of Operation, Recent Corporate Developments.

ITEM 6. EXHIBITS.

|Exhibit |                                                                                 
|------- | --------------------------------------------------------------------------------
|Number  | Description of Exhibits                                                         
|3.1     | Articles of
      Incorporation.(1)                                             
|3.2     | Amendment to Articles of Incorporation filed
      March 14, 2005.(1)           
|3.3     | Certificate of Change to
      Authorized Capital effective January 17, 2006.(2)

12

---

|Exhibit |                                                                                                                                                                                                                                            
|------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Number  | Description of Exhibits                                                                                                                                                                                                                    
|3.4     | Certificate of Amendment to Articles
      of Incorporation  name change to Vitavea Inc. effective
      November 27, 2006.(8)                                                                                                          
|3.5     | Bylaws.(1)                                                                                                                                                                                                                                 
|10.1    | GNU General Public License (GPL).(1)                                                                                                                                                                                                       
|10.2    | GNU Lesser General Public License (LGPL).(1)                                                                                                                                                                                               
|10.3    | Sun Industry Standards Source License
      (SISSL).(1)                                                                                                                                                                                    
|10.4    | Loan Agreement with Blackpointe Holdings Inc.(3)                                                                                                                                                                                           
|10.5    | Share Purchase Agreement among
      the Company, Vitavea AG, WKB Beteiligungsgesellschaft mbH, Crystalwood Holdings
      Ltd., Peter J. Hoyle and Lina Zhou, dated for reference the 31stday
      of July, 2006.(4)                     
|10.6    | Extension Letter from WKB Beteiligungsgesellshaft
      mbH dated August 23, 2006.(5)                                                                                                                                                      
|10.7    | Loan Agreement between the Company
      and Vitavea AG dated as of August 31, 2006.(5)                                                                                                                                                    
|10.8    | Promissory Note executed by Vitavea AG as of August
      31, 2006.(5)                                                                                                                                                                     
|10.9    | Extension Letter from WKB Beteiligungsgesellshaft
      mbH dated September 15, 2006.(6)                                                                                                                                                   
|10.10   | Loan Agreement between the Company and Vitavea
      AG dated as of October 3, 2006.(7)                                                                                                                                                    
|10.11   | Promissory Note executed by Vitavea
      AG as of October 3, 2006.(7)                                                                                                                                                                     
|10.12   | Loan Agreement between the Company and Vitavea
      AG dated as of October 11, 2006.(7)                                                                                                                                                   
|10.13   | Promissory Note executed by Vitavea
      AG as of October 11, 2006.(7)                                                                                                                                                                    
|10.14   | Amendment Agreement to the Loan Agreement between
      the Company and Black  Pointe Holdings Inc., dated for reference
      the 16thday of November, 2006.(8)                                                                           
|10.15   | Purchase Agreement between Vitavea
      AG, Carmen Otho-Loefert, Meba Medizinische Badebetriebsgesellschaft MBH
      and Adolf Baur GmbH, dated for reference the 28thday of November,
      2006 (translated from German to English).(8)
|14.1    | Code of Ethics.(1)                                                                                                                                                                                                                         
|31.1    | Certification
      of Chief Executive Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley
      Act of 2002.                                                                                                                 
|31.2    | Certification of Chief
      Financial Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley
      Act of 2002.                                                                                                                 
|32.1    | Certification
      of Chief Executive Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002.                                                                                                                 
|32.2    | Certification of Chief
      Financial Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002.                                                                                                                 

(1) Filed with the SEC as an exhibit to our Registration Statement
  on Form SB-2 originally filed on May 4, 2005, as amended.
  (2) Filed with the SEC as an exhibit to our Current Report on Form 8-K filed
  on January 17, 2006.
  (3) Filed with the SEC as an exhibit to our Quarterly Report on Form 10-QSB
  filed on June 14, 2006.
  (4) Filed with the SEC as an exhibit to our Current Report on Form 8-K filed
  on August 9, 2006.
  (5) Filed with the SEC as an exhibit to our Current Report on Form 8-K filed
  on September 5, 2006.
  (6) Filed with the SEC as an exhibit to our Current Report on Form 8-K filed
  on September 21, 2006.
  (7) Filed with the SEC as an exhibit to our Current Report on Form 8-K filed
  on October 19, 2006.
  (8) Filed with the SEC as an exhibit to our Annual Report on Form 10-KSB filed
  on February 13, 2007.

13

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|      |                      |  |     | VITAVEA INC.                         
|----- | -------------------- |  | --- | -------------------------------------
|      |                      |  |     |                                      
|      |                      |  |     |                                      
|Date: | March
      26, 2007 |  | By: | /s/
      Roger Liere                
|      |                      |  |     | ROGER LIERE                          
|      |                      |  |     | Chief Executive Officer and President
|      |                      |  |     | (Principal Executive Officer )       

|Date: | March
      26, 2007 |  | By: | /s/
      John Boschert                               
|----- | -------------------- |  | --- | ------------------------------------------------------
|      |                      |  |     | JOHN BOSCHERT                                         
|      |                      |  |     | Chief Financial Officer, Secretary and
      Treasurer
|      |                      |  |     | (Principal Accounting Officer)                        

---